ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...
CricBuzz

BCCI modifies age verification procedure; allows 2nd bone test

The Age Verification Programme (AVP), practised to curb age-fudging in junior cricket, has been modified by the Board of Control for Cricket in India (BCCI). Starting this year, the BCCI will permit a ...
B2B Marketing Magazine

Marketing Areas

The Global ABM Conference 2025 delegate brochure is packed with all the information you'll need ahead of booking your ticket. Our second ever Global B2B Marketing Agencies Benchmarking Report is back ...